Related Experiment Video
Updated: May 28, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Norcantharidin analogues: a patent review (2006 - 2010)
1Shaoxing University, School of Chemistry and Chemical Engineering, Zhejiang P.R China. wwdlp@126.com
Introduction:
Norcantharidin (7-oxabicyclo [2.2.1] heptane-2,3-dicarboxylic anhydride) is the demethylated form of cantharidin. Norcantharidin not only has strong anticancer activity, but also eliminates most side-effects in the urinary system, does not cause myelosuppression and increases the number of white blood cells. With structural modification, norcantharidin analogues show potential anticancer activities.
Areas Covered:
A comprehensive patent review of norcantharidin analogues from 2006 to 2010 is presented. Protein phosphatase 1, 2A, 2B and 5 inhibitors are described. The review summarizes the new compounds and lays the foundation for seeking more effective anticancer compounds.
Expert Opinion:
Although norcantharidin has improved activity and toxicity, the effects routinely do not satisfy the current clinical need. Exploring better analogues is vital for changing the current situation, but norcantharidin is a good lead compound.
Related Concept Videos
Drug Nomenclature
Antiviral Nucleoside Inhibitors
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Anthelminthic Agents
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Drug Regulation
